Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo

Anti-Cancer Drugs

Volumn 22, Issue 5, 2011, Pages 444-453

  Liu, Xianzhe ^a,b   Choy, Edwin ^a   Harmon, David ^a   Yang, Shuhua ^b   Yang, Cao ^b   Mankin, Henry ^a   Hornicek, Francis J ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

BI 2536; osteosarcoma; PLK1

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; CASPASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLO LIKE KINASE 1; PROTEIN MCL 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TIME; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BONE NEOPLASMS; CELL CYCLE PROTEINS; CELL DIVISION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G2 PHASE; HUMANS; MICE; MICE, NUDE; MITOSIS; OSTEOSARCOMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955068894     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834513f4     Document Type: Article

References (31)

1. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ. Osteosarcoma. J Am Acad Orthop Surg 2009; 17:515-527.
2. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 2008; 10:315-327.
3. Bacci G, Ferrari S, Mercuri M, Longhi A, Capanna R, Tienghi A, et al. Neoadjuvant chemotherapy for extremity osteosarcoma: preliminary results of the Rizzoli's 4th study. Acta Oncol 1998; 37:41-48. (Pubitemid 28179799)
4. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol coss-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9:893-899. (Pubitemid 28440449)
5. Trent JC. Rapid evolution of the biology and treatment of sarcoma. Curr Opin Oncol 2008; 20:393-394.
6. Tan ML, Choong PF, Dass CR. Osteosarcoma: conventional treatment vs. gene therapy. Cancer Biol Ther 2009; 8:106-117.
7. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe plk1 depletion. Mol Cell Biol 2006; 26:2093-2108. (Pubitemid 43346913)
8. Martin BT, Strebhardt K. Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle 2006; 5:2881-2885. (Pubitemid 44953940)
9. Van Vugt MA, Medema RH. Getting in and out of mitosis with polo-like kinase-1. Oncogene 2005; 24:2844-2859. (Pubitemid 40638094)
10. Duan Z, Ji D, Weinstein EJ, Liu X, Susa M, Choy E, et al. Lentiviral shRNA screen of human kinases identifies plk1 as a potential therapeutic target for osteosarcoma. Cancer Lett 2010; 292:220-229.
11. Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, et al. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009; 8:3024-3035.
12. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al. Bi 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17:316-322. (Pubitemid 46241881)
13. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007; 17:304-315.
14. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008; 26:5511-5517.
15. Hofheinz RD, Al-Batran SE, Hochhaus A, Jager E, Reichardt VL, Fritsch H, et al. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 2010; 16:4666-4674.
16. Lourda M, Trougakos IP, Gonos ES. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein j. Int J Cancer 2007; 120:611-622. (Pubitemid 44969033)
17. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of mcf-10a mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30:256-268. (Pubitemid 36677560)
18. Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, et al. Polo-like kinase 1 (plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the plk1 inhibitor BI 2536. Cancer Res 2010; 70:1513-1523.
19. Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M. Identification of polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 2009; 69:1916-1923.
20. Renner AG, Dos Santos C, Recher C, Bailly C, Creancier L, Kruczynski A, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009; 114:659-662.
21. Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, et al. 3-D tumor model for in-vitro evaluation of anticancer drugs. Mol Pharm 2008; 5:849-862.
22. Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, et al. Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci 2009; 100:2268-2274.
23. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-330.
24. Colnaghi R, Wheatley SP. Liaisons between survivin and plk1 during cell division and cell death. J Biol Chem 2010; 285:22592-22604.
25. Glinsky GV. Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated polycomb group (pcg) protein chromatin silencing pathway. Cell Cycle 2006; 5:1208-1216. (Pubitemid 43845382)
26. Noh EJ, Lim DS, Jeong G, Lee JS. An hdac inhibitor, trichostatin a, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun 2009; 378:326-331.
27. Noh EJ, Lim DS, Lee JS. A novel role for methyl cpg-binding domain protein 3, a component of the histone deacetylase complex, in regulation of cell cycle progression and cell death. Biochem Biophys Res Commun 2009; 378:332-337.
28. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234:397-405. (Pubitemid 27243915)
29. Cogswell JP, Brown CE, Bisi JE, Neill SD. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25c function. Cell Growth Differ 2000; 11:615-623. (Pubitemid 32042984)
30. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996; 135:1701-1713. (Pubitemid 27036434)
31. Liu X, Erikson RL. Polo-like kinase (plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100:5789-5794 (Pubitemid 36576886)